FDA Warns Singulair Users and Physicians

Greg Owen

Attorney

0 CommentsPrint ArticleSubscribe

The Food and Drug Administration (FDA) informed healthcare professionals and patients alike of their findings regarding the possible links between the use of Singulair and changes in mood and behavior. Their concerns pertain to suicidal thinking, changed behavior and indeed suicide.

Merck, the manufacturer of Singulair, is stressing that this warning is based on a small number of studies. (Still cause for concern, I'd say). Singulair is a leukotriene receptor antagonist. It is used to prevent exercise-induced asthma and to treat asthma and the symptoms of allergic rhinitis.
Last year Merck's Singulair reached $4.3 billion in sales. Their Singulair labeling does not current mention risk of possible mood/behavior changes and/or suicidal thoughts.

Additional Information Pertaining to Dangerous and Defective Products